Skip to main content
RaQualia Pharma Inc. logo

RaQualia Pharma Inc. — Investor Relations & Filings

Ticker · 4579 ISIN · JP3967150008 T Professional, scientific and technical activities
Open in API
Filings indexed 89 across all filing types
Latest filing 2026-05-20 Regulatory Filings
Country JP Japan
Listing T 4579

About RaQualia Pharma Inc.

https://www.raqualia.com/en/index.html

RaQualia Pharma Inc. is a research and development-focused pharmaceutical company that specializes in the discovery and development of innovative small molecule compounds. The company's primary activities involve conducting exploratory research to identify novel drug candidates and advancing them through preclinical and clinical studies. Its business model centers on creating value by out-licensing the intellectual property of these compounds to other pharmaceutical companies for final development and commercialization. A key product originating from its research is tegoprazan (K-CAB®), a potassium-competitive acid blocker used for treating gastroesophageal reflux disease and other acid-related conditions.

Recent filings

Filing Released Lang Actions
米Velovia Pharma, LLCによるオプション権行使に伴う一時金受領のお知らせ
Regulatory Filings Classification · 92% confidence The document is a corporate announcement notifying the market of a licensing option exercise by a partner (Velovia Pharma) and the resulting lump‐sum payment. It is not an earnings release, share issue, dividend, or management report—it’s a general regulatory notice of a material business event filed via JPX. Therefore, it falls under the fallback category for miscellaneous regulatory filings.
2026-05-20 Japanese
（訂正）2026年12月期（第18期）第１四半期　決算説明資料
Investor Presentation Classification · 90% confidence The document is a corrected “2026年12月期（第19期）第1四半期 決算説明会資料” comprising the full slide deck used for the Q1 financial results briefing, including detailed P&L, balance sheet, cash flows, operational highlights, strategy and pipeline charts. It is not merely an announcement of a report (“menu”) but contains substantive financial data, analysis and presentation materials targeted at investors. This matches the definition of an Investor Presentation (IP).
2026-05-18 Japanese
国際学会DDW 2026における胃酸分泌抑制剤tegoprazanの第III相臨床試験データ発表に関するお知らせ
Regulatory Filings
2026-05-07 Japanese
取締役に対する譲渡制限付株式報酬としての新株式発行の払込完了に関するお知らせ
Regulatory Filings
2026-04-24 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification regarding the accuracy of the company's Annual Securities Report (有価証券報告書). According to the 'Certification Rule', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type, as they do not contain the actual financial statements themselves. FY 18
2026-03-23 Japanese
有価証券報告書－第18期(2025/01/01－2025/12/31)
Annual Report Classification · 100% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which is the standard Japanese equivalent of an Annual Report (10-K). It contains detailed financial statements, management indicators, and corporate information for the fiscal year ending December 31, 2025. It is not an announcement or a summary, but the full statutory filing. FY 2025
2026-03-23 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.